Based on all the information above, we hypothesize that NSCLC patients carrying EGFR activating mutations produce aberrant m5C methylation upon EGFR-TKIs treatment, leading to intrinsic resistance to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.